Table 1.
Demographic information of sub-cohorts analyzed in the study
| Aim | DBS center [N/female] | Age [years] | Disease Duration | UPDRS- III Baseline (Med OFF) [Points] | Levodopa response [%] | UPDRS-III Improvement (Med OFF DBS ON) [%] | LEDD reduction (%) | Postop imaging | |
|---|---|---|---|---|---|---|---|---|---|
| Discovery Cohort (N = 129) | Establishment of multisymptom model | Würzburg (44/12) | 60.4 ± 8.20 | 12.6 ± 4.5 | 49.84 ± 12.35 | 61.8 ± 18.4 | 49.3 ± 24.8 | 61.4 ± 25.1 | CT |
| Berlin (51/18)74 | 60.0 ± 7.90 | 10.4 ± 3.9 | 38.6 ± 12.9 | 53.5 ± 17.2 | 45.3 ± 23.0 | 52.8 ± 41.6 |
MRI (N = 45) CT (N = 6) |
||
| Amsterdam (34/8) | 50.53 ± 9.80 | 12.7 ± 6.1 | 47.03 ± 15.5 | 68.8 ± 26.1 | 46.9 ± 15.7 | 41.82 ± 38.17 | CT | ||
| Validation cohort I (N = 93) | Validation & Replication of multi symptom model |
Würzburg (52/19) |
59.22 ± 3.99 | 10.84 ± 4.18 | 42.46 ± 16 | 62.39 ± 17.44 | 46.37 ± 22.23 | 50.94 ± | CT |
|
Beijing (41/20) |
65.38 ± 7.18 | 8.85 ± 3.77 | 53.26 ± 18.05 | 52.65 ± 15.31 | 52.65 ± 15.13 | 32 ± 23 |
MRI (N = 8) CT (N = 33) |
||
| Validation cohort II (N = 10) | Monopolar Review Data: Validation of Symptom Specificity of model |
Cologne (10/4; 186 stimulation settings) |
61.54 ± 9.15 | 9.72 ± 3.03 | 44.2 ± 17.5 | 22.7 ± 14.5 | 27.99 ± 34.6 | 48 ± 11 | CT |
| Prospective feasibility cohort (N = 5) | Prospective Application of Cleartune |
Würzburg (5/1) |
60.6 ± 4.98 | 14 ± 4 | 49.8 ± 22.1 | 62.8 ± 15.87 |
65.4 ± 12.05 [Cleartune: 73.1 ± 11.8] |
57 ± 24.43 | CT |
An overview of demographic information across all sub-cohorts used in the study. The discovery cohort represents the original cohort of patients used to develop the symptom library. We used validation cohorts I and II to replicate the findings from the discovery cohort. The prospective cohort included five patients, who were enrolled to test the applicability of Cleartune in a clinical setting.